NCT02637115View on ClinicalTrials.gov

Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 20, 2018

Study Completion Date

February 20, 2018

Conditions
Metabolic Syndrome xGlucose Metabolism DisordersDyslipidemiasObesity
Interventions
DIETARY_SUPPLEMENT

Placebo

Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)

DIETARY_SUPPLEMENT

Live Akk 9

Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)

DIETARY_SUPPLEMENT

Live Akk 10

Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)

DIETARY_SUPPLEMENT

Killed Akk

Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila

Trial Locations (1)

1200

Cliniques universitaires Saint-Luc, Brussels

All Listed Sponsors
collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

Patrice D. Cani

OTHER

NCT02637115 - Evaluation of the Effects Associated With the Administration of Akkermansia Muciniphila on Parameters of Metabolic Syndrome | Biotech Hunter | Biotech Hunter